CanAssist Breast (CAB), an immunohistochemistry (IHC) and artificial intelligence-based prognostic test, was developed on Hormone receptor-positive (HR +), HER2/neu-negative (HER2-) breast tumors from Indian patients and validated in retrospective gl...
Accurate interpretation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scores 0 and 1+ is crucial for treating HER2-low breast cancer patients with antibody-drug conjugates. To improve diagnostic precision, we developed...
Presently, pathologists need to stain biopsy samples with standard and antibody-based immunocytochemistry (ICC) reagents for final diagnosis. Antibody reagents take hours to days to perform staining, along with requiring specialized equipment and tec...
Digital pathology enables automatic analysis of histopathological sections using artificial intelligence. Automatic evaluation could improve diagnostic efficiency and find associations between morphological features and clinical outcome. For developm...
The increasing complexity of cancer diagnostics and treatment selection has placed a growing burden on pathologists, particularly in the evaluation of immunohistochemical (IHC) biomarkers. In gastroesophageal cancers (GEC), both adenocarcinoma and sq...
PURPOSE: Tumor-infiltrating lymphocytes (TILs) play a crucial role in host antitumor processes. High level of TILs is associated with better outcomes for patients. We aim to automatically quantify TILs without any nuclei annotation and further constr...
Immunohistochemistry (IHC) examination is essential to determine the tumour subtypes, provide key prognostic factors, and develop personalized treatment plans for breast cancer. However, compared to Hematoxylin and Eosin (H&E) staining, the preparati...
BACKGROUND: Treatment with HER2-targeted therapies is recommended for HER2-positive breast cancer patients with HER2 gene amplification or protein overexpression. Interestingly, recent clinical trials of novel HER2-targeted therapies demonstrated pro...
Programmed death-ligand 1 (PD-L1) is an important biomarker increasingly used as a predictive marker in breast cancer immunotherapy. Immunohistochemical quantification remains the standard method for assessment. However, it presents challenges relate...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.